News coverage about Alimera Sciences (NASDAQ:ALIM) has been trending somewhat positive on Tuesday, Accern Sentiment reports. The research firm identifies positive and negative press coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Alimera Sciences earned a news sentiment score of 0.17 on Accern’s scale. Accern also assigned press coverage about the biopharmaceutical company an impact score of 45.5751601894408 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the next few days.

Here are some of the news stories that may have impacted Accern Sentiment’s rankings:

ALIM has been the topic of several recent research reports. Zacks Investment Research upgraded Alimera Sciences from a “sell” rating to a “hold” rating in a report on Tuesday, August 29th. ValuEngine downgraded Alimera Sciences from a “sell” rating to a “strong sell” rating in a report on Monday, September 18th. Cowen restated a “buy” rating on shares of Alimera Sciences in a report on Thursday, November 2nd. Finally, HC Wainwright restated a “buy” rating and set a $5.00 price target on shares of Alimera Sciences in a report on Wednesday, August 30th. Two research analysts have rated the stock with a sell rating and three have given a buy rating to the stock. The company has a consensus rating of “Hold” and an average price target of $3.38.

Shares of Alimera Sciences (NASDAQ:ALIM) opened at $1.30 on Tuesday. The company has a quick ratio of 4.65, a current ratio of 4.84 and a debt-to-equity ratio of -0.71. Alimera Sciences has a 1-year low of $1.06 and a 1-year high of $1.72.

WARNING: “Somewhat Favorable Press Coverage Somewhat Unlikely to Impact Alimera Sciences (ALIM) Stock Price” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this news story on another website, it was stolen and republished in violation of US & international copyright & trademark laws. The correct version of this news story can be accessed at https://www.thecerbatgem.com/2017/12/05/somewhat-favorable-press-coverage-somewhat-unlikely-to-impact-alimera-sciences-alim-stock-price.html.

About Alimera Sciences

Alimera Sciences, Inc (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina.

Insider Buying and Selling by Quarter for Alimera Sciences (NASDAQ:ALIM)

Receive News & Stock Ratings for Alimera Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences Inc. and related stocks with our FREE daily email newsletter.